“The stem cells were unable to self-renew, which resulted in long-term and irreversible impairment of tumour growth. In other words, the cancer was permanently shut down.”
Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.
“This is the first step toward clinically applying the principles of cancer stem cell biology to control cancer growth and advance the development of durable cures,” says principal investigator Dr. John Dick about the findings published online today in Nature Medicine.
He talks about the research in this video.
Dr. Dick pioneered the cancer stem cell field by first identifying leukemia stem cells (1994) and colon cancer stem cells (2007). He is also renowned for isolating a human blood stem cell in its purest form – as a single stem cell capable of regenerating the entire blood system – paving the way for clinical use (2011). Dr. Dick holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at University Health Network’s Princess Margaret Cancer Centre and McEwen Centre for Regenerative Medicine. He is also a Professor in the Department of Molecular Genetics, University of Toronto, and Director of the Cancer Stem Cell Program at the Ontario Institute for Cancer Research.
In pre-clinical experiments, the research team replicated human colon cancer in mice to determine if specifically targeting the stem cells was clinically relevant. First, the researchers identified that the gene BMI-1, already implicated in maintaining stem cells in other cancers, is the pivotal regulator of colon cancer stem cells and drives the cycle of self-renewal, proliferation and cell survival. Next, the team used an existing small-molecule inhibitor to successfully block BMI-1, thus demonstrating the clinical relevance of this approach.
Lead author Dr. Antonija Kreso writes: “Inhibiting a recognized regulator of self-renewal is an effective approach to control tumor growth, providing strong evidence for the clinical relevance of self-renewal as a biological process for therapeutic targeting.”
Dr. Dick explains: “When we blocked the BMI-1 pathway, the stem cells were unable to self-renew, which resulted in long-term and irreversible impairment of tumour growth. In other words, the cancer was permanently shut down.”
The Latest Google Headlines on: Colon cancer
The Latest Bing News on: Colon cancer
- What Anyone With Ulcerative Colitis Needs to Know About Colorectal Canceron January 22, 2020 at 11:40 am
How does ulcerative colitis affect colorectal cancer risk? We’re about to get into the more nerve-wracking information here, so before we do, let’s be really clear: Having ulcerative colitis is in no ...
- Sociodemographic factors may influence survival among young adults with colorectal canceron January 22, 2020 at 11:15 am
Young adults with colorectal cancer who resided in areas with the lowest incomes and high school graduation rates had a 24% increased risk for death than their counterparts in areas with the highest ...
- Exact Sciences Gains After Rival's Colorectal Cancer Screening Product Falls Shorton January 22, 2020 at 9:30 am
Exact Sciences shares are higher. Analysts who follow the company contend biopsy results presented by Freenome didn't match the detection level of EXAS's Cologuard.
- Colorectal Cancer Therapeutics Market to Witness Robust Expansion throughout the Forecast 2019-2025on January 22, 2020 at 1:45 am
The Global Colorectal Cancer Therapeutics Market Report provides a complete analysis of the market. The Report focuses on manufacturers, suppliers, segmentation according to the application, major ...
- Gut bacteria may be one culprit for increase of colorectal cancer in younger peopleon January 22, 2020 at 12:28 am
A bacteria typically linked to periodontal disease, Fusobacterium nucleatum (F. nuc), could play an important role in the rising incidence of colorectal cancer in people under the age of 45. Another ...
- Global Colorectal Cancer Therapeutics Market 2019...on January 21, 2020 at 5:00 pm
Technavio has been monitoring the global colorectal cancer therapeutics market since 2015, and the market is poised to grow by USD 994.94 million during 2019-2023, progressing at a CAGR of almost 3% ...
- Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposiumon January 21, 2020 at 4:00 am
/PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various ...
- Colorectal Cancer Therapeutics Market 2020 Future Trends, Top Players, Key Benefits, Business Opportunities and Regional Analysis 2029on January 19, 2020 at 9:23 pm
Global News for Colorectal Cancer Therapeutics Market Study 2020-2029, by Segment (Diagnostics, Therapeutics), Playing a Pivotal Role in Expanding by (Hospitals, Clinic, Research institutions), ...
- Dana-Farber researcher: High-dose vitamin D can delay colorectal cancer progressionon January 18, 2020 at 3:28 pm
Advanced stage, incurable, metastatic colorectal cancer patients given high doses of vitamin D along with chemotherapy can stave off progression of the deadly disease and improve their overall ...
- National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera™ MRD Testing in Stage II-III Colorectal Canceron January 15, 2020 at 4:42 am
/PRNewswire/ -- Today Natera, Inc. (NASDAQ: NTRA) announced an agreement with the National Cancer Center (NCC) Japan to launch the CIRCULATE-IDEA trial ...
The Latest Google Headlines on: Therapeutic stem cells
The Latest Bing News on: Therapeutic stem cells
- Feed has no items.